Advertisement
LIMN vs RNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIMN is a Hold and RNA is a Hold.
LIMN sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for LIMN moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LIMN as a result. In 34 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 32%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for LIMN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 61 cases where LIMN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 48%.
Following a +9.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIMN advanced for three days, in 53 of 90 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
LIMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.349) is normal, around the industry mean (3.498). P/E Ratio (-0.106) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. LIMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RNA's RSI Indicator ascending out of oversold territory
The RSI Indicator for RNA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 28 of the 33 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for RNA just turned positive on October 07, 2026. Looking at past instances where RNA's MACD turned positive, the stock continued to rise in 29 of 38 cases over the following month. The odds of a continued upward trend are 76%.
Following a +0.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNA advanced for three days, in 197 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 61 cases where RNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNA as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for RNA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.665) is normal, around the industry mean (3.498). P/E Ratio (-1.533) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.537) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. RNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RNA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 80 | |
P/E GROWTH RATING 1..100 | 15 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| LIMN | RNA | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 48% | 2 days ago 74% |
| Momentum ODDS (%) | 7 days ago 32% | 2 days ago 88% |
| MACD ODDS (%) | N/A | 6 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 48% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 84% |
| Advances ODDS (%) | 2 days ago 59% | 3 days ago 77% |
| Declines ODDS (%) | 6 days ago 73% | 7 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 57% | N/A |
| Aroon ODDS (%) | 2 days ago 55% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LIMN’s FA Score shows that 1 FA rating(s) are green while RNA’s FA Score has 1 green FA rating(s).
- LIMN’s FA Score: 1 green, 4 red.
- RNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LIMN’s TA Score shows that 3 TA indicator(s) are bullish while RNA’s TA Score has 3 bullish TA indicator(s).
- LIMN’s TA Score: 3 bullish, 4 bearish.
- RNA’s TA Score: 3 bullish, 4 bearish.
Price Growth
LIMN (@Biotechnology) experienced а -0.72% price change this week, while RNA (@Biotechnology) price change was -5.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
LIMN is expected to report earnings on Nov 12, 2026.
RNA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
LIMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, LIMN has been loosely correlated with FTH. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if LIMN jumps, then FTH could also see price increases.
| Ticker / NAME | Correlation To LIMN | 1D Price Change % | ||
|---|---|---|---|---|
| LIMN | 100% | +2.59% | ||
| FTH - LIMN | 35% Loosely correlated | +1.89% | ||
| UPB - LIMN | 35% Loosely correlated | -5.59% | ||
| IMMP - LIMN | 34% Loosely correlated | -8.95% | ||
| RNA - LIMN | 32% Poorly correlated | -1.79% | ||
| ALDX - LIMN | 31% Poorly correlated | -1.08% | ||
More | ||||
RNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.
| Ticker / NAME | Correlation To RNA | 1D Price Change % | ||
|---|---|---|---|---|
| RNA | 100% | -1.79% | ||
| DYN - RNA | 64% Loosely correlated | -3.76% | ||
| PBYI - RNA | 49% Loosely correlated | -3.04% | ||
| DSGN - RNA | 48% Loosely correlated | -1.39% | ||
| IDYA - RNA | 48% Loosely correlated | -0.87% | ||
| NTLA - RNA | 42% Loosely correlated | -7.76% | ||
More | ||||